Introduction {#Sec1}
============

The inflammatory response is driven by the release of inflammatory mediators and the recruitment of circulating leukocytes, which become activated at the site of inflammation and release further mediators. Generally, the inflammatory response is resolved by the release of endogenous anti-inflammatory mediators and the accumulation of intracellular negative regulatory factors (Nathan [@CR28]). Failure to regulate inflammation adequately is important in autoimmunity and infection and may play a role in chronic diseases such as coronary artery disease, obesity and cancer (Lin and Karin [@CR24]). Anti-cytokine therapies, such as anti-tumor necrosis factor-α, can successfully treat some chronic inflammatory diseases (Feldmann and Maini [@CR11]).

Suppressor of cytokine signalling (SOCS) proteins are intracellular inhibitors of cytokine signalling that act in a classical negative feedback loop (Croker et al. [@CR4]). SOCS3 may have profound effects on the regulation of immunity and inflammation by affecting the activation, development and homeostatic functions of all lineages involved in immune and inflammatory responses (O'Shea and Murray [@CR29]). For example, SOCS3 limits the activities of the haematopoietic growth factors granulocyte colony stimulating factor (G-CSF) and granulocyte--macrophage colony stimulating factor (GM-CSF) (Croker et al. [@CR4]). Administration of G-CSF in vivo mimics emergency granulopoiesis during infection. In SOCS3 conditional knockout mice, this process is grossly exacerbated, with neutrophil infiltration and destruction of liver, lung, muscle and spinal tissue, resulting from increased intensity and duration of G-CSF-induced Stat3 activation (Croker et al. [@CR3]; Kimura et al. [@CR17]).

Stimulation of macrophages with lipopolysaccharide (LPS) leads to the production of various cytokines including IL-1, TGF-β, IL-10, and IL-6, all of which upregulate SOCS3 expression (Dimitriou et al. [@CR7]). Toll-like receptor (TLR) stimulation can also upregulate SOCS3 expression independently of cytokine induction (Dalpke et al. [@CR6]). Indeed SOCS3 is one of the most abundantly induced proteins in LPS-stimulated macrophages (Yoshimura et al. [@CR37]). SOCS3 then mediates feedback inhibition of LPS-induced macrophage activation (Berlato et al. [@CR1]; Donnelly et al. [@CR9]). SOCS3-transfected murine macrophages produce reduced levels of LPS-induced NO~2~^−^, TNF-α, IL-6, and GM-CSF. The extent of this inhibition is similar to that seen in wild type cells treated with LPS and IL-10 (Berlato et al. [@CR1]; Dimitriou et al. [@CR7]). Accordingly, primary peritoneal SOCS3−/− macrophages exhibit impaired IL-10 regulation of LPS-induced NO~2~^−^ and TNF-α (Berlato et al. [@CR1]). Macrophages from mice that lack SOCS3 expression in all haematopoietic and endothelial lineages produce more IL-6 following IL-1 stimulation (Wong et al. [@CR35]). SOCS3 mRNA is induced rapidly following cytokine stimulation, being detectable within 20 min of IL-6 stimulation and declining to basal levels after 8 h (Larsen and Ropke [@CR18]). Notwithstanding, SOCS3 has also been shown to positively regulate TLR4 signalling and M1 polarisation of macrophages in mouse and rat (Wang et al. [@CR34]; Liu et al. [@CR25], [@CR26]).

SOCS1 and SOCS3 exert their negative feedback via several distinct mechanisms: (1) blocking JAK catalytic domain-STAT protein substrate interactions to terminate signal propagation; (2) competitively inhibiting JAK and STAT binding to phosphotyrosine-based docking sites on activated cytokine receptors, such as the shared cytokine subunit gp130; (3) targeting their binding partners for ubiquitination and proteasome degradation (Dimitriou et al. [@CR7]). The SOCS3 protein inhibits signal transduction via various receptors, including the IL-6R, IFN-γR, GM-CSFR, IL-12 receptor β2, erythropoietin receptor, IL-27Rα, IL-31Rα, G-CSF receptor, and leptin receptor (Dimitriou et al. [@CR7]; Dalpke et al. [@CR6]; Xu et al. [@CR36]).

However, SOCS3 does not bind or inhibit signalling via the IL-10R, explaining the divergent activities of the pro-inflammatory cytokine IL-6 and the immunoregulatory cytokine IL-10 following TLR stimulation (Dimitriou et al. [@CR7]; Yoshimura et al. [@CR37]). Induction of SOCS has been suggested as a means of immune evasion for bacteria, viruses and parasites, for example *Mycobacterium bovis BCG* (Imai et al. [@CR15]; Dalpke et al. [@CR6]). SOCS3 expression in dendritic cells (DCs) is important in regulating the production of cytokines able to direct naïve T-cell differentiation towards a T~h2~ or a T~reg~ phenotype (Li et al. [@CR21]; Dimitriou et al. [@CR7]). Naïve T~h~ cells express high levels of SOCS3, which are transiently decreased after antigenic stimulation, allowing increased proliferation in response to IL-2. Both unstimulated and stimulated T~reg~ cells exhibit low SOCS3 levels (Dimitriou et al. [@CR7]). A negative regulatory role for SOCS3 in IL-1 signalling has been observed in B-cells, in which SOCS3 negatively regulates IL-1R signalling pathways (Dimitriou et al. [@CR7]).

SOCS3 knockout leads to placental defects, possible disturbances in intrahepatic erythropoiesis and embryonic lethality (Roberts et al. [@CR31]; Marine et al. [@CR27]; Larsen and Ropke [@CR18]). Mice with a conditional deletion of the Socs3 gene in haematopoietic and endothelial cells die as young adults due to severe inflammatory lesions in the peritoneal and pleural cavities (Croker et al. [@CR5]). Transgenic overexpression of SOCS3 also leads to embryonic lethality, while SOCS3 overexpression in T-cells leads to increased Th2 differentiation (Dalpke et al. [@CR6]). SOCS3 mRNA expression has been identified in foetal liver, primarily during the stage of fetal liver erythropoiesis (Marine et al. [@CR27]), and, at low levels, in adult mouse spleen, thymus and lung (Starr et al. [@CR33]). A limited immunohistochemical study demonstrated SOCS3 expression in colonic epithelium and lamina propria leucocytes in biopsies from normal individuals and ulcerative colitis patients (Li et al. [@CR22]).

The intracellular localisation of SOCS proteins has been controversial, with most authors reporting only a cytoplasmic localisation (Ding et al. [@CR8]), although Lee and colleagues observed cytoplasmic and nuclear localisation (Lee et al. [@CR20]). Nuclear localisation, however, seems inconsistent with SOCS proteins mediating their effects solely at the cell membrane (Dimitriou et al. [@CR7]; Ding et al. [@CR8]). To date detailed analysis of the expression pattern and intracellular localisation of SOCS proteins in human tissue samples has been limited by the availability of specific anti-human SOCS3 antisera that work on formalin fixed tissue.

Here we report the subcellular localisation of SOCS3 fusion proteins in transfected cells and we validate an anti-SOCS3 polyclonal rabbit serum and use it to determine the expression pattern of SOCS3 protein in a wide range of human tissues under normal and inflammatory conditions. By means of immunohistochemistry (IHC), we demonstrate both cytoplasmic and nuclear expression of SOCS3 in vitro and in vivo. SOCS3 expression in tissue samples may be a useful marker of cells undergoing acute and, to a lesser extent, chronic cytokine stimulation in vivo.

Materials and methods {#Sec2}
=====================

SOCS1 and SOCS3 fusion proteins {#Sec3}
-------------------------------

Human SOCS1 and SOCS3 coding sequences were amplified by PCR and cloned into the expression plasmid pcDNA3.1, together with the GFP gene. The coding region of the recombinant plasmids was confirmed by DNA sequencing.

IL-4 luciferase assay {#Sec4}
---------------------

Murine TARC luciferase reporter plasmids, SOCS expression vectors and hCMV β-galactosidase plasmids were co-transfected into sub-confluent CHO cells using Genejuice^®^ (Merck) in serum free Optimem medium (InVitrogen) (Liddiard et al. [@CR23]). After 18 h, cells were stimulated with 20 ng ml^−1^ Interleukin-4 (R&D Systems) for 6 h. Whole cell extracts were prepared in Reporter Lysis Buffer (Promega) and luciferase enzyme activity was determined using the Promega luciferase assay kit and β-galactosidase enzyme activity in the same lysates was assayed by measuring conversion of the colorimetric substrate chlorophenol red-β-D-galactopyranoside (Boeringer Mannheim) at 550 nm as described previously (Liddiard et al. [@CR23]).

Preparation of transfectants and western blot {#Sec5}
---------------------------------------------

HEK293T cells were seeded into a six well plate and transfected with GFP, SOCS2 or SOCS3 expression plasmids using Genejuice^®^ (Merck). Total cell lysates were prepared 36 h post transfection and western blots performed. Total protein (40 μg) was resolved on an SDS--PAGE gel and western blotted onto nitrocellulose (in duplicate). The blot was incubated with rabbit polyclonal anti-SOCS3 sera (ab16030 and ab53984) (ABCAM, Cambridge, UK) and bands detected with goat anti-rabbit horseradish peroxidase (HRP) (Biorad) and chemiluminescence (SuperSignal West Pico, Pierce). The blot was stripped and re-probed with rabbit anti-tubulin polyclonal antiserum (Cell Signaling Technology) to demonstrate equal protein loading in all lanes.

Preparation of transfected paraffin wax cell blocks {#Sec6}
---------------------------------------------------

Cell blocks of HEK293 cells transiently transfected with SOCS2, SOCS3 or GFP were prepared using the Shandon Cytoblock^®^ Cell Preparation System (Thermo Fisher Scientific, Massachusetts, USA) as per the manufacturer's instructions and fixed in 4% formalin, followed by processing following standard histological techniques.

Lipopolysaccharide stimulation and immunofluorescent staining of human peripheral blood mononuclear cells {#Sec7}
---------------------------------------------------------------------------------------------------------

Human PBMCs were isolated from buffy coat preparations (National Blood Service, London, UK) using Ficoll-Paque plus according to manufacturer's instructions (GE Healthcare, Little Chalfont, UK). Cells were plated in 8 well LabTek chamber slides (Nunc, Rochester NY) and cultured in X-Vivo 10 medium (Lonza, Wokingham, UK) plus 1% autologous serum for 7 days. Cells were stimulated for 4 h with 100 ng/ml LPS from Escherichia coli strain 055:B5 (Sigma--Aldrich, Gillingham, UK). After 4 h, medium was removed, cells were fixed in 4% paraformaldehyde for 15 min then permeabilised for 5 min in 0.25% Triton X-100/PBS. Non-specific binding was blocked for 30 min with blocking solution (PBS/0.1% Triton X-100/1% BSA/200 μg/ml human IgG). Anti-SOCS3 antibody (1:50 dilution, ab53984, Abcam) or isotype control (rabbit IgG, Jackson Immunoresearch) was added and cells stained overnight at 4°C. PE conjugated secondary antibody (1:200 dilution, goat anti-rabbit IgG, Jackson Immunoresearch) was added for 2 h at room temperature. Nuclei were counterstained for 5 min with DAPI (Sigma--Aldrich). Slides mounted with fluorescent mounting medium (Sigma--Aldrich). Images were captured using a Zeiss 510 META confocal microscope.

Histological samples {#Sec8}
--------------------

All tissue samples were obtained with full ethical approval from the National Research and Ethics Service (REC reference 04/Q1604/21). A wide range of normal human tissues (*n* = 31) were obtained from the Cellular Pathology Department, John Radcliffe Hospital, Oxford, UK, and used to construct tissue microarrays (core diameter 1 mm), using the MTA-1 manual arrayer (Beecher Instruments, Wisconsin, USA). Two cores from each donor block were taken to increase the sample area. Whole sections of tissue were similarly obtained.

Antibodies and immunostaining {#Sec9}
-----------------------------

The following primary antibodies were used: rabbit polyclonal against SOCS3 (ab53984, ABCAM, Cambridge, UK) and myeloperoxidase (AO398, Dako, Ely, UK); mouse monoclonal antibodies against DC-SIGN (clone DC28, R&D Systems, Minneapolis, USA); CD3 (clone LN10) and CD56 (clone 1B6, Leica Biosystems Newcastle Ltd, Newcastle, UK); mouse monoclonal antibodies against CD20 (clone L26), CD31 (clone JC70), CD61 (Y2/51), CD68 (clone PGM1) and glycophorin C (clone ret40f) were kindly donated by Prof. K. Gatter, Nuffield Department of Clinical Laboratory Sciences, Oxford, UK. Immunostaining was performed using standard techniques and a Bond Max™ immunostaining machine (Leica Biosystems Newcastle Ltd, Newcastle, U.K.). Heat mediated antigen retrieval was performed on all tissue sections using the high pH Epitope Retrieval 2 solution (Leica Microsystems, Wetzlar, Germany) for 20 min at 100°C. This was followed by a 5 min peroxidase block as per the manufacturers' kit and instructions (Leica Microsystems, Wetzlar, Germany). For single labelled immunohistochemisty, the peroxidase/DAB Bond™ Polymer Refine Detection System (Leica Microsystems, Wetzlar, Germany) was used for visualisation. For double labelled immunohistochemisty, the peroxidase/DAB Bond™ Polymer Refine Detection System and alkaline phosphatase/fast red Bond™ Polymer AP Red Detection System (Leica Microsystems, Wetzlar, Germany) were used for visualisation. All slides were counterstained using Mayer's haematoxylin and mounted in DePeX (VWR International, Lutterworth, UK). As a negative control for the anti-SOCS3 antiserum, a section was immunostained with normal rabbit serum at an equivalent concentration (0.0013 mg/ml).

Cell counting {#Sec10}
-------------

Four 20× microscope fields were selected for counting for each tissue sample. Three full sections of each condition and corresponding normal tissue were used. The same areas were marked and counted on each slide.

Statistical analysis {#Sec11}
--------------------

The Minitab 15^®^ statistics package (Minitab, State College, PA, USA) was used for all statistical analyses. Results from cell population counts were converted to proportions and recorded as a percentage e.g. percentage of CD68^+^ cells expressing SOCS3. Analysis of correlation was performed using the non-parametric Spearman's rank correlation coefficient (r). This was achieved by performing a Pearson correlation coefficient on ranked data. To identify differences in population medians the Mann--Whitney U test was used.

Results {#Sec12}
=======

Antibody validation {#Sec13}
-------------------

To establish the specificity of the SOCS3 antibodies we performed western blots of GFP, SOCS2 and SOCS3 transfected cell lysates. Incubation with anti-SOCS3 ab53984 detected a single band of the correct molecular weight in SOCS3 transfected cell lysate and this band was not detected in lysates prepared from GFP or SOCS2 transfected cells (Fig. [1](#Fig1){ref-type="fig"}a, upper panel). Stripping the blots and re-probing with an anti-tubulin antibody demonstrated equal protein loading in each lane (Fig. [1](#Fig1){ref-type="fig"}a, middle panel). SOCS3 was not detected with a second commercially available SOCS3 antiserum (Fig. [1](#Fig1){ref-type="fig"}a, lower panel). Single labelled immunohistochemistry (IHC) using the anti-SOCS3 antibody ab53984 demonstrated positive staining in the SOCS3 CHO cell transfectants in formalin fixed paraffin blocks but did not identify protein expression in the GFP or SOCS2 CHO cell transfectants (Fig. [1](#Fig1){ref-type="fig"}b), thus confirming the specificity of the antibody. Of note immunohistochemical staining showed that SOCS3 protein was detectable in both the nuclear and cytoplasmic compartments of transfected cells. To characterise the antiserum further, immunohistochemical staining of formalin fixed paraffin embedded human tonsil tissue was undertaken, using rabbit serum as a negative control. Positive cytoplasmic and nuclear staining of a range of mononuclear cells was seen with the anti-SOCS3 serum (Fig. [1](#Fig1){ref-type="fig"}c,upper panel), but not with normal rabbit serum (Fig. [1](#Fig1){ref-type="fig"}c, lower panel). Similarly, immunofluorescent staining of lipopolysaccharide (LPS) stimulated peripheral blood mononuclear cells showed strong, predominantly nuclear staining (Fig. [1](#Fig1){ref-type="fig"}d, upper panel), while no staining was seen with an isotype control antibody (Fig. [1](#Fig1){ref-type="fig"}d, lower panel).Fig. 1Detection of SOCS3 protein in transiently transfected cells. **a** Lysates prepared from HEK 293 cells transiently transfected with pcDNA3.1 or the indicated SOCS expression vectors were fractionated by SDS PAGE and transferred to HyBond membrane. Anti-SOCS3 antisera (ab53984 and ab16030) were used for western blotting at 1/1000 dilution and an anti-rabbit IgG HRP antibody was used at 1/2000 dilution as secondary antibody. **b** Transiently transfected 293 cells were harvested and fixed with 4% formalin before embedding and sectioning for IHC with anti SOCS3 antiserum ab53984 as described in "[Methods and materials](#Sec2){ref-type="sec"}", 293 cells were transfected with SOCS3, GPF, or SOCS2 (40× magnification). **c** Normal tonsil immunostained for SOCS3 using rabbit polyclonal antiserum ab53984 at a final concentration of 0.0013 mg/ml (upper panel) compared with a negative control of normal tonsil immunostained with normal rabbit serum at the same concentration (*lower panel*). *Scale bar* (*lower right*) pertains to both panels and represents 50 μm. Panel D: SOCS3 is expressed in both the cytoplasm and nucleus of primary human macrophages stimulated with lipopolysaccharide (LPS). PBMCs (cultured for seven days) were stimulated with 100 ng/ml LPS for 4 h. Cells were fixed, permeabilised and stained with anti-SOCS3 antibody (*upper panel*) or isotype control (*lower panel*) followed by goat anti-rabbit PE-conjugated secondary antibody. Nuclei were counterstained with DAPI. Cells with compact, unstained nuclei are lymphocytes. Data are representative of two independent donors

Sub-cellular localisation of SOCS1 and SOCS3 in transfected CHO cells {#Sec14}
---------------------------------------------------------------------

In order to study the sub-cellular localisation of SOCS3 in living cells we transiently transfected CHO cells with SOCS1-GFP and SOCS3-GFP fusion proteins and observed them using confocal microscopy. Figure [2](#Fig2){ref-type="fig"} shows the distribution of GFP alone, SOCS1-GFP and SOCS3-GFP in transfected CHO cells. GFP staining was distributed throughout the cell localising in both the nucleus and cytoplasm (Fig. [2](#Fig2){ref-type="fig"}a). SOCS1-GFP and SOCS3-GFP were localised predominantly in the nucleus, but were also present to a lesser extent in the cytoplasm (Fig. [2](#Fig2){ref-type="fig"}b, c). No fluorescence was detected in non-transfected cells (data not shown). We tested whether the presence of the GFP-tag would inhibit the ability of the SOCS protein to inhibit Jak/STAT signalling using the IL-4 inducible murine TARC promoter in transiently transfected CHO cells. As shown in Fig. [3](#Fig3){ref-type="fig"}, the presence of the GFP tag does not affect the ability of the SOCS1 or SOCS3 proteins to inhibit IL-4 signalling. However, we cannot state categorically that the presence of the GFP-tag does not alter other properties of the SOCS proteins, including subcellular localisation.Fig. 2Localisation of SOCS1 and SOCS3 in transfected CHO cells using confocal microscopy**.** Plasmids encoding GFP-alone (**a**), SOCS1-GFP (**b**), and SOCS3-GFP (**c**) were transiently transfected into CHO cells grown on glass coverslips in 24 well plates using GeneJuice. 24 h post-transfection the coverslips were removed, washed in PBS, fixed using 4% paraformaldehyde and observed using confocal microscopy. Fluorescence images are on the *left* and phase contrast images on the *right*. Results are representative of three independent experimentsFig. 3TARC-luciferase assay in CHO cells showing that SOCS1-GFP and SOCS3-GFP are functional. CHO cells (2 × 10^6^) were transiently transfected with 500 ng mTARC-luciferase, 100 ng hCMV β-galactosidase, 200 ng STAT6 and 200 ng of the indicated SOCS expression vector. Cells were transiently transfected for 18 h then stimulated with IL-4 (20 ng ml^−1^) for 6 h before harvest in luciferase lysis buffer (Promega). Results are expressed as luciferase activity normalized for beta galactosidase activity and are representative of three independent experiments and data are presented as mean ± SEM

SOCS3 Immunohistochemistry on normal human tissue {#Sec15}
-------------------------------------------------

In normal human tissues, SOCS3 immunopositivity was widespread with varying intensity. Cells with lower levels of expression demonstrated exclusively cytoplasmic SOCS3 expression, while appreciable levels of nuclear SOCS3 were visible in cells with higher cytoplasmic expression levels. SOCS3 expression could be seen in endothelial cells, macrophages, DCs, lymphocytes, neutrophils and in various epithelial cells in a wide range of normal human tissues, including tonsil, skin, testis (Fig. [4](#Fig4){ref-type="fig"}a), cervix, endometrium, fallopian tube (Fig. [4](#Fig4){ref-type="fig"}b), kidney, small and large intestine and lung (Table [1](#Tab1){ref-type="table"}, Fig. [4](#Fig4){ref-type="fig"}). Epithelia that did not express SOCS3 included salivary gland, oesophagus, stomach pancreas, liver, adrenal, parathyroid and ovary. None of these tissues contained constitutive lymphoid infiltrates or significant numbers of other leucocytes. SOCS3 protein showed an interesting distribution in lymphoid tissue, including spleen, lymph node, tonsil and the small and large intestinal lamina propria. Strong immunopositivity was seen in tingible body macrophages, interdigitating DCs and endothelial cells in sinuses and germinal centre B lymphocytes. B lymphocytes in the mantle and marginal zone showed little SOCS3 expression, as did paracortical T lymphocytes. In the thymus, cells mediating positive and negative selection, such as macrophages, DCs and epithelial cells, showed strong SOCS3 immunopositivity, while thymocytes were largely SOCS3-negative.Fig. 4SOCS3 expression in normal human tissues. **a**--**c** show single immunostaining using the peroxidase technique (*brown*), while **d**--**f** show double immunostaining with SOCS3 detection by the peroxidase technique (*brown*) and detection of other antigens by the alkaline phosphatase technique (*red*). **a** Testicular tubules (TUB) showing strong cytoplasmic and weaker nuclear SOCS3 immunopositivity, together with weaker immunopositivity in adjacent macrophages (MAC). **b** Fallopian tube epithelium (EP) showing strong cytoplasmic and weaker nuclear SOCS-immunopositivity. **c** Bone marrow showing strong cytoplasmic and nuclear SOCS3 immunopositivity in cells of myeloid lineage (MYEL) including monocytes and neutrophils and their precursors, weak cytoplasmic immunopositivity in megakaryoctes (see Fig. [5](#Fig5){ref-type="fig"}h) and minimal immunopositivity in cells of erythroid lineage (ERY). **d** Small intestinal mucosa immunostained for SOCS3 (*brown*) and CD68 (red) demonstrating nuclear and cytoplasmic SOCS3 expression in some macrophages/dendritic cells (*arrows*), in addition to SOCS3 immunopositivity in epithelium (EP) and a range of other leucocytes. **e** Lymph node immunostained for SOCS3 (*brown*) and DC-SIGN (*red*) demonstrating strong nuclear and weaker cytoplasmic SOCS3 immunopositivity (*arrows*) in interdigitating dendritic cells in the paracortex. Various lymphocytes and macrophages also show strong nuclear SOCS3 immunopositivity (*arrowheads*). **f** Duodenal submucosal vascular/lymphatic channels demonstrating strong nuclear and cytoplasmic SOCS3 immunopositivity (brown, arrows) in CD31-positive (*red*) endothelial cells. *Scale bars* (*bottom right* of **a**--**f**) represent 50 m. **g**. Magnified view of **b** to demonstrate cells with cytoplasmic staining only (*arrowheads*) compared with those with both nuclear and cytoplasmic staining (*arrows*). **h** Magnified view of **c** to demonstrate a megakaryocyte with cytoplasmic staining only (*arrowhead*) compared with myeloid cells showing both nuclear and cytoplasmic staining (*arrows*). *Scale bars* (bottom right of **a**--**f**) represent 15 m. (Color figure online)Table 1SOCS3 expression pattern in normal tissuesTissueMorphology of SOCS3-expressing cellsMacrophages/DCsEndothelial cellsEpithelial cellsOther/commentsTonsilPositiveNegativePositivePositive in germinal centre B-cells, tingible body macrophages, sinus and interdigitating dendritic cells; very weakly positive on some other lymphocytes.Lymph nodePositiveSinus endothelial cells positiveNot applicablePositive in germinal centre B-cells, tingible body macrophages and interdigitating dendritic cells; very weakly positive on some other lymphocytes.SpleenStrongly positiveWeakly positive, particularly sinus endotheliumNot applicableLymphocytes negativeThymusStrongly positiveWeakly positiveStrongly positiveAlmost all thymocytes negative, occasional cells very weakly positiveSkinOccasionally positiveVascular endothelial cells positiveWeakly positive, particularly appendagesScattered leucocytes are occasionally positive.Salivary glandPositiveNegativeNegativeOesophagusPositiveStrongly positiveNegativeStomachPositivePositiveNegativeSmall bowelPositivePositiveStrongly positiveLymphocytes and plasma cells largely negative, except intraepithelial lymphocytes, which are strongly positive.AppendixPositiveNegative or occasionally weakly positivePositiveColonPositiveWeakly positiveWeakly positiveLymphocytes largely negative.LiverKupffer cells negativeNegativeNegativeGallbladderOccasional positive cellsWeakly positiveWeakly positiveOccasional positive leucocytesPancreasPositiveWeakly positiveNegativeSome islet cells positive.LungAlveolar macrophages, positivePositivePositive in both type I and type II pneumocytesThyroidWeakly positiveWeakly positiveWeakly positiveScattered weakly positive leucocytesParathyroidNegativeWeakly positiveNegativeAdrenalStrongly positiveNegativeNegativeKidneyNot applicableNegativeTubular epithelium positive particularly in atrophic tubules.BladderPositiveWeakly positiveStrongly positiveScattered stromal leucocytes positiveProstateNegativeNegativeVery weakly positiveTestisPositiveNegativePositiveSpermatogenic cells strongly positiveBreastNegativePositiveNegativeCervixPositiveNegativeVery weakly positive.Intraepithelial lymphocytes of endocervix strongly positive. Scattered stromal leucocytes occasionally weakly positive.EndometriumPositivePositivePositiveScattered stromal eclls weakly positive; scant leucocytes present, some of which (including CD56^+^ natural killer cells) are positive.Fallopian tubeNone seenNegativeWeakly positiveOccasional leucocytes are weakly positive.OvaryPositivePositiveNegativeStroma weakly positive.Amniotic membranePositivePositiveNegativeStromal cells strongly positivePlacentaNegativeNegativeSyncytiotrophoblast & cytotrophoblast positive

Double labelled immunohistochemistry confirmed SOCS3 expression in CD68^+^ macrophages/DCs (Fig. [4](#Fig4){ref-type="fig"}d), DC-SIGN^+^ DCs (Fig. [4](#Fig4){ref-type="fig"}e), and CD31^+^ endothelial cells (Fig. [4](#Fig4){ref-type="fig"}f). SOCS3 was also expressed by some CD3-positive T-lymphocytes, some CD20-positive B-lymphocytes and occasional CD56-positive natural killer cells in normal tissues (Table [1](#Tab1){ref-type="table"} and data not shown). The lymphocytes, macrophages, DCs and endothelial cells showed a very variable pattern of SOCS3 expression, ranging from no expression to strong expression with variable cytoplasmic/nuclear distribution. In general, judging expression levels by immunohistochemical staining intensity, cells demonstrating nuclear expression of SOCS3 protein had higher cytoplasmic SOCS3 expression levels.

In bone marrow (Fig. [4](#Fig4){ref-type="fig"}c), strong SOCS3 immunostaining was seen in macrophages/DCs and in maturing cells of myeloid lineage with features of monocytic or granulocytic (neutrophil or eosinophil) differentiation, in addition to patchy weaker immunopositivity in some megakaryocytes and endothelial cells (Fig. [4](#Fig4){ref-type="fig"}). The identity of the cells was confirmed by double immunostaining for myeloperoxidase, glycophorin C and CD61 (data not shown). Cells of myeloid, macrophage and endothelial cell lineage expressed high levels of SOCS3 in both a cytoplasmic and nuclear location, while megakaryocytes expressed intermediate levels of SOCS3 with none being present in the nuclei. Cells of erythroid lineage expressed very little SOCS3 and showed no nuclear staining.

SOCS3 expression in inflamed human tissues {#Sec16}
------------------------------------------

We examined SOCS3 expression in acute, chronic and granulomatous inflammatory conditions (Fig. [5](#Fig5){ref-type="fig"}, Table [2](#Tab2){ref-type="table"}). SOCS3 expression was seen in the majority of leucocytes, particularly neutrophils, macrophages and lymphocytes, in inflammatory lesions, regardless of the phenotype of the inflammation. However, SOCS3 immunostaining appeared to be most intense in areas of acute inflammation, e.g., acute appendicitis (Fig. [5](#Fig5){ref-type="fig"}a), acutely inflamed radicular cysts, in crypt abscesses in ulcerative colitis (Fig. [5](#Fig5){ref-type="fig"}b), adjacent to deep fissuring ulcers and in endothelial cells and circulating neutrophils in Crohn's disease (Fig. [5](#Fig5){ref-type="fig"}c), and in the central but not the peripheral parts of granulomas in various conditions (Fig. [5](#Fig5){ref-type="fig"}d--f). In these conditions, the cells expressing high levels of SOCS3 appeared to be predominantly neutrophils, together with a smaller number of macrophages and other leucocytes. A higher level of SOCS3 expression than that of the corresponding normal tissue could also be seen in some epithelial and endothelial cells adjacent to areas of intense acute inflammation, for example crypt abscesses of ulcerative colitis (Fig. [5](#Fig5){ref-type="fig"}b) and inflamed radicular cysts.Fig. 5SOCS3 expression in inflamed human tissues. All panels show double immunostaining with SOCS3 detection by the peroxidase technique (*brown*) and CD68 detection by the alkaline phosphatase technique (*red*). **a**. Acute inflammation in acute appendicitis shows moderate to strong SOCS3 immunopositivity in CD68^+^ cells (*arrows*) and strong SOCS3 immunopositivity in a range of other leucocytes, particularly neutrophils (*arrowheads*). **b** In the colon in ulcerative colitis, high levels of nuclear and cytoplasmic SOCS3 immunopositivity were seen in neutrophils in crypt abscesses (*arrowheads*), as well as in epithelium adjacent to areas of acute inflammation (EP). A small focus of surface ulceration is shown and the underlying macrophages/dendritic cells (MAC) show strong SOCS3 expression. **c** Submucosal blood vessel in Crohn's disease containing abundant SOCS3^+^ neutrophils (*arrows*) and showing strong endothelial SOCS3 expression, with adjacent SOCS3^+^ macrophages/dendritic cells (*arrowheads*). **d** Giant cell (*arrow*) from the submucosa in colonic Crohn's disease, showing strong nuclear and weaker cytoplasmic SOCS3 immunopositivity, together with macrophages/dendritic cells (*arrowheads*) showing similar SOCS3 expression. **e** Non-necrotising granulomas of sarcoidosis (one granuloma is *circled*) in which macrophages show moderate nuclear and cytoplasmic SOCS3 immunopositivity with marked accentuation in the centre of the granuloma (*arrow*). **f** Granuloma in temporal arteritis showing similar features to **e**. All scale bars (*bottom right* of each panel) 50 m. (Color figure online)Table 2Inflammatory conditions, their normal counterparts and changes in percentage of CD68^+^ cells expressing SOCS3 in various inflammatory conditionsInflammatory ConditionMean % CD68^+^ cells expressing SOCS3 (counted in 4 fields) (%)Type of InflammationCorresponding Normal TissueMean % CD68^+^ cells expressing SOCS3 (counted in 4 fields) (%)% CD68^+^ cells expressing SOCS3 in inflamed compared with normal tissueLymph node sarcoidosis62.35GranulomatousNormal lymph node27.42↑ *p* = 0.0014Crohn's Disease43.10GranulomatousNormal colon11.04↑ *p* \< 0.0001UC40.03Acute-on-chronicNormal colon11.04↑ *p* \< 0.0001Acute appendicitis32.69AcuteNormal colon11.04↑ *p* = 0.0020Hidradenitis suppurativa24.60GranulomatousNormal skin18.81↗ *p* = 0.1572Radicular cyst40.65Acute-on-chronicBenign fibroepithelial polyp34.33↗ *p* = 0.3123Temporal arteritis53.29GranulomatousNormal temporal artery31.46↑ *p* = 0.0239

In order to investigate the effects of inflammation on expression of SOCS3 by macrophages and DCs, the percentage of CD68^+^ cells (macrophages/DCs) that expressed SOCS3 was determined in four 20× representative microscope fields in 3 cases of each of 7 pathological conditions with acute, chronic or granulomatous inflammation and compared with results for corresponding normal tissue. Each individual inflammatory condition demonstrated a higher percentage of CD68^+^ cells expressing SOCS3 than the corresponding normal tissue, with a significant *p* value in the majority of cases (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec17}
==========

In this study, we have used GFP-tagged forms of the human SOCS3 protein both to validate anti-SOCS3 antisera and investigate the subcellular localisation of SOCS3 protein. We demonstrate, by means of transfection immunohistochemical studies and immunofluorescent staining of LPS-stimulated peripheral blood mononuclear cells, that SOCS3 protein may be present in both the nucleus and cytoplasm, in keeping with a previous study using SOCS3 transfectants (Lee et al. [@CR20]). In vivo, we show that nuclear SOCS3 immunostaining is seen only in cells with high levels of cytoplasmic expression, consistent with in vitro data demonstrating SOCS3 nuclear translocation only when its levels increase (Lee et al. [@CR20]). The transfectants used in our study are likely to overexpress SOCS3, explaining the observed, predominantly nuclear localisation of the GFP-tagged SOCS3 protein in these experiments. There has been one previous limited immunohistochemical study of SOCS3 expression in human intestine (Li et al. 2010). While Li et al. describe cytoplasmic expression of SOCS3(Li et al. 2010), close examination of their immunohistochemical figures shows a predominantly cytoplasmic distribution in epithelial cells, but demonstrates a cytoplasmic and nuclear distribution of SOCS3 in leucocytes with morphological appearances of macrophages, DCs or lymphocytes in the large intestinal lamina propria, in agreement with our data.

Previous studies using mRNA analysis identified SOCS3 mRNA in normal mouse thymus, lung, spleen (Starr et al. [@CR33]) and foetal liver (Marine et al. [@CR27]), and in human T-cells, monocytes and macrophages in vitro (Isomaki et al. [@CR16]; Rakshit et al. [@CR30]). Using immunohistochemistry we were able not only to confirm the expression of SOCS3 protein in normal human adult thymus, lung, liver and spleen, but also to identify the major positive cell types as macrophages, immature myeloid DCs and endothelial cells. Additionally, in normal tissues, SOCS3 is expressed by neutrophils, some B and T-lymphocytes, occasional natural killer cells and many types of epithelium. Our demonstration of SOCS3 expression by epithelia at a number of sites is also in keeping with the study by Li et al. in which the authors show expression of SOCS3 by colonic epithelial cells (Li et al. 2010). The figures in their study demonstrate SOCS3 expression by lamina propria leucocytes with morphological appearances suggesting that they might be macrophages, DCs or lymphocytes, although the authors do not comment on expression by these cell types or determine their identity. However, the SOCS3 expression pattern is consistent with the pattern we describe here, both in normal colon and in ulcerative colitis.

While epithelia adjacent to lymphoid aggregates or leucocytic infiltrates (e.g., small and large intestine, tonsil, cervix) express SOCS3, epithelia with few adjacent leucocytes are generally SOCS3 negative, e.g., salivary gland, oesophagus, stomach, pancreas and liver. Many epithelia express cytokine receptors, for example for TNF-α, IL-1 and IL-6 (Fritz et al. [@CR12]), which are known to induce SOCS3. Epithelia adjacent to lymphoid aggregates or leucocytic infiltrates may be subject to repeated stimulation by these cytokines, leading to the induction of SOCS3 expression detectable by IHC.

SOCS3 shows an interesting distribution in lymphoid tissue, including spleen, lymph node, tonsil and the small and large intestinal lamina propria. Strong immunopositivity is seen in tingible body macrophages, interdigitating DCs, DCs in sinuses and germinal centre B lymphocytes. Mantle/marginal zone B and paracortical T lymphocytes show little SOCS3 expression. Data from mouse studies indicate only very low levels of SOCS3 expression in progenitor B cells with a gradual increase in SOCS3 levels as B cells become more mature (Le et al. [@CR19]). SOCS3 can inhibit focal adhesion kinase activation, preventing B cell adhesion to VCAM-1, increasing B-cell motility (Le et al. [@CR19]). It is likely that germinal centre B-cells require significant motility to allow interaction with follicular DCs and T-cells. Mantle/marginal zone B-cells may remain in lymphoid areas for longer periods, thus requiring less motility and possibly explaining their lower levels of SOCS3 expression. An alternative explanation is discrepancies between the human and mouse immune systems in patterns of SOCS3 expression. Our observation of minimal expression of SOCS3 by paracortical T-lymphocytes appears incongruous with the observation in vitro that naïve T~h~ cells express high levels of SOCS3, which are transiently decreased after antigenic stimulation, allowing increased proliferation in response to IL-2 (Dimitriou et al. [@CR7]). One possibility is that the lymphoid tissue we examined contained predominantly T lymphocytes responding to antigen and thus undergoing activation/proliferation, with concomitantly decreased SOCS3 levels. Alternatively, there may be differences between the mouse immune system, in which much previous work has been done (Dimitriou et al. [@CR7]), and the human immune system.

In the thymus, cells mediating positive and negative selection, such as macrophages, DCs and epithelial cells, showed high levels of SOCS3 expression. Little expression was seen in thymocytes, in keeping with a report showing that SOCS3 conditional knockout mice demonstrate normal T-cell development in the thymus, suggesting SOCS3 may not play a crucial role in thymocytes (Chen et al. [@CR2]).

Cells expressing SOCS3 in normal tissues may be subject to cytokine stimulation. At sites where few cytokines are likely to be present, there may be some other, as yet undetermined mechanism of SOCS3 induction causing regulation of cytokine or TLR-mediated activation, possibly to prevent inappropriate induction of an inflammatory or immune response. Tissue macrophages or DCs may, for example, express SOCS3 to prevent them producing pro-inflammatory/immune cytokines and/or expressing crucial co-stimulatory molecules that might otherwise induce an immune or inflammatory response, with the inherent risks of breaking immunological tolerance or causing inflammatory damage (Hart [@CR13]). Similarly, certain endothelia, particularly lymph node sinus endothelium and possibly some small blood vessel endothelium, may present antigen to lymphocytes to induce immunological tolerance (Soilleux et al. [@CR32]). SOCS3 may be important at these sites in preventing the production of pro-inflammatory/immune cytokines. If such cells did present antigen to T lymphocytes, they might induce tolerance rather than immunity in these lymphocytes.

In bone marrow, cells of the granulocytic and monocytic lineage express high levels of SOCS3 (Fig. [4](#Fig4){ref-type="fig"}c), in keeping with data from SOCS3 conditional knockout mice demonstrating that SOCS3 is necessary to limit the activities of the haematopoietic growth factors G-CSF and GM-CSF (Croker et al. [@CR4]; Croker et al. [@CR3]; Kimura et al. [@CR17]). Expression of SOCS3 by myeloid cells may also explain the appreciable levels of SOCS3 mRNA previously detected in foetal liver (Marine et al. [@CR27]). Mutations in the tyrosine kinase JAK2 are identified in the majority of patients with myeloproliferative neoplasms, such as essential thrombocythaemia, a chronic proliferative neoplasm of megakaryocytes. JAK2, particularly when constitutively activated by mutation, phosphorylates a tyrosine residue in SOCS3 to inactivate it and escape its inhibition (Elliott et al. [@CR10]; Hookham et al. [@CR14]). Our demonstration for the first time of SOCS3 expression by normal megakaryocytes provides additional evidence for this mechanism.

In keeping with our data showing high levels of SOCS3 expression in LPS-stimulated peripheral blood mononuclear cells, particularly cells morphologically resembling macrophages, we observed a marked increase in SOCS3 expression in inflamed tissues, in many types of leucocyte, particularly neutrophils, macrophages and lymphocytes, as well as in epithelia, endothelia and fibroblasts. Given our observation of high levels of SOCS3 expression in maturing myeloid cells in bone marrow, it is not possible to determine whether there is rapid induction of neutrophil SOCS3 expression at sites of inflammation following their recruitment to these sites or whether neutrophils that constitutively express SOCS3 are recruited to the inflamed site. Our striking observation of the significant accentuation of SOCS3 expression in the centre of granulomas compared with the peripheral parts. It is likely that there is both a higher level of cytokines, such as IL-6, and of microbial products at the centre of the granuloma, causing increased levels of SOCS3 induction via both cytokine receptors and TLRs. The relatively short half-life of SOCS3 would mean that its expression relied on repeated or continuous induction, mirroring local cytokine or microbial product levels. Following IL-6 stimulation of myeloid cell lines, mRNA from SOCS-3 is detectable within 20 min, declining to basal levels after 8 h (Larsen and Ropke [@CR18]). Our observation of more intense immunostaining, suggesting higher SOCS3 expression levels, in acute than chronic or granulomatous inflammation is also consistent with the time course of SOCS3 induction, as well as possibly being related to higher cytokine levels in acute inflammation.

In summary, we have demonstrated both cytoplasmic and nuclear localisation of the regulatory protein SOCS3 and have performed the first detailed expression study on SOCS3 by means of immunohistochemistry on human tissues. Commensurate with its induction by a range of cytokines, with a rapid time course of induction and subsequent rapid downregulation, a very significant increase in expression at sites of inflammation, particularly in areas where the inflammation is acute and/or cytokines are present at highest levels. This makes SOCS3 a potential marker of sites at which there are significant levels of cytokines and it may be a more stable and useful marker of ongoing inflammation than the cytokines themselves.
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